Cat. No. ARG0864
The CRBN Knockout U?937 Cell Line is a CRISPR/Cas9?edited human knockout model targeting cereblon, the substrate receptor for the CUL4A?DDB1?RBX1 E3 ligase. In the U?937 histiocytic lymphoma background, CRBN disruption allows precise investigation of IMiD?redirected degradation of transcription factors like IKZF1 and CK1??, central to drug response. This tool supports mechanistic studies of ubiquitin?proteasome signaling, validation of targeted degraders, and analysis of protein homeostasis in a monocytic lymphoma context. Core techniques include co?immunoprecipitation, Western blotting, drug sensitivity assays, and flow cytometry. Contact Ascent Research for technical details.
| Host Cell | U-937 |
| Age | 37 years |
| Sex of Donor | Male |
| Gene Name | CRBN |
| Gene Identifier | NCBI Gene ID 51185 |
| Temperature | 37°C |
| Atmosphere | 5% CO₂ |
| Sterility testing | Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination. |
| Mycoplasma testing | Negative for mycoplasma through PCR analysis |
| Pathogens | Cells tested negative for HIV-1, HBV, and HCV. |
Intended Use: This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer: Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use.
This product is provided "AS IS". For Research Use Only. Not for human or animal therapeutic use.
The CRBN Knockout U-937 Cell Line is a CRISPR/Cas9-edited human knockout cell line designed for loss?of?function studies of cereblon (CRBN) in a histiocytic lymphoma background. This engineered product provides a defined genetic background to interrogate CRBN?dependent ubiquitination processes and drug responses, without asserting clonality or specific editing outcomes. By disrupting the CRBN gene, the model serves as a powerful tool for dissecting the substrate?receptor function of the CRL4 E3 ligase complex in a hematologic cellular context.
The parental U?937 cell line was originally established from the pleural effusion of a patient with diffuse histiocytic lymphoma and displays monocytic characteristics, making it a widely used model for monocyte/macrophage biology and lymphoid malignancies. U?937 cells are amenable to a variety of transfection, drug treatment, and functional assay protocols, enabling robust investigation of signaling pathways and cellular responses relevant to both innate immunity and cancer.
CRBN functions as a substrate receptor for the CUL4A?CDDB1?CRBX1 (CRL4) E3 ubiquitin ligase complex. Under homeostatic conditions, it mediates the ubiquitination and proteasomal degradation of target proteins such as MEIS2 and GLI2, thereby regulating limb morphogenesis and other developmental pathways. Immunomodulatory imide drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, bind to CRBN and re?direct its substrate specificity toward neo?substrates, most notably the transcription factors IKZF1 (Ikaros), IKZF3 (Aiolos), and casein kinase 1?? (CK1??/CSNK1A1). This drug?induced degradation underlies the therapeutic and teratogenic effects of IMiDs. Upstream regulators such as the SP1 transcription factor and interferon?gamma also modulate CRBN expression, further integrating CRBN into growth and immune signaling networks.
In the U?937 histiocytic lymphoma model, CRBN knockout enables specific investigation of IMiD?mediated signaling and resistance mechanisms. Because U?937 cells are naturally sensitive to IMiD?induced apoptosis and growth inhibition, ablation of CRBN provides a clean genetic control for confirming on?target drug effects and for distinguishing CRBN?dependent from CRBN?independent pathways. The knockout also facilitates studies of CRBN??s endogenous role in protein homeostasis and its interaction with the HSP90 chaperone network. These features make the cell line highly relevant for multiple myeloma and myelodysplastic syndrome research, where IMiDs are standard?of?care agents.
Typical applications of this knockout cell line include mechanistic dissection of CRL4 E3 ligase signaling, validation of small?molecule modulators of CRBN, analysis of protein degradation dynamics using ubiquitination assays and co?immunoprecipitation, and profiling of drug sensitivity via MTT?based viability assays. The model is also suited for genome?wide CRISPR screens, flow?cytometric assessment of apoptosis and cell?cycle changes, and transcriptomic studies by RT?qPCR or RNA sequencing. Researchers can employ the line to model teratogenicity or to engineer novel CRBN?based degrader molecules, thereby advancing targeted protein degradation strategies. For technical inquiries or custom cell?line generation, please contact Ascent Research.
